Switch theme
Sign up to access all valuation multiples
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
2003
143
LTM Revenue $20.7M
LTM EBITDA -$6.8M
$503M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Medincell has a last 12-month revenue of $20.7M and a last 12-month EBITDA of -$6.8M.
In the most recent fiscal year, Medincell achieved revenue of $9.8M and an EBITDA of -$20.0M.
Medincell expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Medincell valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $10.7M | $9.8M | XXX | XXX | XXX |
| Gross Profit | $4.4M | n/a | XXX | XXX | XXX |
| Gross Margin | 41% | NaN% | XXX | XXX | XXX |
| EBITDA | -$28.4M | -$20.0M | XXX | XXX | XXX |
| EBITDA Margin | -266% | -203% | XXX | XXX | XXX |
| Net Profit | -$26.6M | -$34.4M | XXX | XXX | XXX |
| Net Margin | -249% | -349% | XXX | XXX | XXX |
| Net Debt | $20.8M | $51.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Medincell's stock price is EUR 14 (or $15).
Medincell has current market cap of EUR 447M (or $481M), and EV of EUR 468M (or $503M).
See Medincell trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $503M | $481M | XXX | XXX | XXX | XXX | $-0.90 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Medincell has market cap of $481M and EV of $503M.
Medincell's trades at 24.2x LTM EV/Revenue multiple, and -74.4x LTM EBITDA.
Analysts estimate Medincell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Medincell and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $503M | XXX | XXX | XXX |
| EV/Revenue | 29.0x | XXX | XXX | XXX |
| EV/EBITDA | -47.9x | XXX | XXX | XXX |
| P/E | -19.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -67.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMedincell's NTM/LTM revenue growth is 110%
Medincell's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Medincell's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Medincell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Medincell and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -8% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -61% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -30% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 50% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 230% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 329% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medincell acquired XXX companies to date.
Last acquisition by Medincell was XXXXXXXX, XXXXX XXXXX XXXXXX . Medincell acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Medincell founded? | Medincell was founded in 2003. |
| Where is Medincell headquartered? | Medincell is headquartered in France. |
| How many employees does Medincell have? | As of today, Medincell has 143 employees. |
| Is Medincell publicy listed? | Yes, Medincell is a public company listed on PAR. |
| What is the stock symbol of Medincell? | Medincell trades under MEDCL ticker. |
| When did Medincell go public? | Medincell went public in 2018. |
| Who are competitors of Medincell? | Similar companies to Medincell include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Medincell? | Medincell's current market cap is $481M |
| What is the current revenue of Medincell? | Medincell's last 12-month revenue is $20.7M. |
| What is the current EBITDA of Medincell? | Medincell's last 12-month EBITDA is -$6.8M. |
| What is the current EV/Revenue multiple of Medincell? | Current revenue multiple of Medincell is 24.2x. |
| What is the current EV/EBITDA multiple of Medincell? | Current EBITDA multiple of Medincell is -74.4x. |
| What is the current revenue growth of Medincell? | Medincell revenue growth between 2023 and 2024 was -8%. |
| Is Medincell profitable? | Yes, Medincell is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
